Per management, installation activity of the CyberKnife and Radixact systems was robust during the first quarter of fiscal 2025, with 22% growth in new installations year over year. By achieving above-market new order growth, order backlog was built in the Chinese market.Rising Product Demand in China: Accuray is witnessing improved customer reception of its technologies globally. Tomo C system is likely to expand ARAY's product portfolio in China, allowing ARAY to compete in the largest and fastest-growing segment of the China radiotherapy market. During the fourth quarter of fiscal 2024, the company received the Precision Treatment Planning System in China for use with the Tomo C radiation therapy system.Management also commented on the China team's ability to ramp up manufacturing production of the Tomo C systems at the Tianjin facility.